Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

10.66

Mkt cap

902M

Volume

656K

High

10.97

P/E Ratio

-6.85

52-wk high

16.99

Low

10.61

Div yield

N/A

52-wk low

6.06

The article lists the stocks that gained and lost the most in Monday's mid-day session. Tupperware Brands Corporation (TUP), Vinco Ventures (BBIG), and Spark Networks (LOV) were among the top gainers, while AppHarvest (APPH), Kodiak Sciences (KOD), and BioCardia (BCDA) were among the top losers. Ryanair Holdings (RYAAY) shares fell by 8.3% after the company reported quarterly results.

Portfolio Pulse from Lisa Levin

July 24, 2023 | 6:54 pm

United Therapeutics Corporation (UTHR) has won an appeal in a patent litigation case against Liquidia Technologies, Inc. The United States Court of Appeals for the Federal Circuit affirmed that Liquidia's proposed Yutrepia™ product infringes a United Therapeutics' patent, preventing the FDA from granting Liquidia final approval for its Yutrepia product until the patent expires in 2027. The court also affirmed that certain claims of another United Therapeutics patent are either invalid or not infringed by Liquidia.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 3:45 pm

Wedbush analyst Andreas Argyrides has reiterated an 'Underperform' rating on Liquidia (NASDAQ:LQDA) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:12 pm

Several stocks experienced significant movement in Thursday's mid-day session. Sigilon Therapeutics (SGTX) shares climbed 523.8% after Eli Lilly agreed to acquire the company. Eco Wave Power Global (WAVE) gained 47.4% after announcing plans for a share repurchase program. Franklin Covey Co. (FC) gained 25.2% following upbeat Q3 results. Carriage Services (CSV) surged 24.4% after its Board initiated a process to explore potential strategic alternatives. The Greenbrier Companies (GBX) gained 23.2% after reporting better-than-expected Q3 results and raising FY23 revenue guidance. On the downside, BioXcel Therapeutics (BTAI) shares dipped 62.2% after releasing topline results from a Phase 3 trial.

Portfolio Pulse from Lisa Levin

June 29, 2023 | 5:52 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Sigilon Therapeutics (SGTX), Immunome (IMNM), Kintara Therapeutics (KTRA), Trxade Health (MEDS), Adamis Pharmaceuticals (ADMP), and Inovio Pharmaceuticals (INO) saw their shares rise, with Sigilon Therapeutics leading the gainers with a 506.6% increase. On the other hand, BioXcel Therapeutics (BTAI), Cormedix (CRMD), Liquidia (LQDA), ATI Physical Therapy (ATIP), Lumos Pharma (LUMO), and Sientra (SIEN) saw their shares decline, with BioXcel Therapeutics leading the losers with a 65.8% decrease.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 5:37 pm

Several stocks recorded losses in Thursday's trading session despite the overall market trading higher. BioXcel Therapeutics shares dropped 62.2% after releasing topline results from a Phase 3 trial. Liquidia Corporation fell 15% as it evaluates a patent claim from United Therapeutics. Other stocks that fell include Xiao-I Corporation, Disc Medicine Opco, Olema Pharmaceuticals, Minerva Neurosciences, Alvotech, Xeris Biopharma Holdings, Lilium N.V., Cricut, TuSimple Holdings, and Zura Bio Limited.

Portfolio Pulse from Lisa Levin

June 29, 2023 | 3:23 pm

Liquidia is reportedly evaluating a patent application claim from United Therapeutics. Further details about the claim are not provided.

Portfolio Pulse from Charles Gross

June 29, 2023 | 11:12 am

Analysts have provided ratings for Liquidia (NASDAQ:LQDA) in the last quarter, with 3 bullish and 1 somewhat bearish. The average 12-month price target for Liquidia is $13.75, a 23.61% decrease from the previous average price target of $18.00.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:00 pm

Needham analyst Serge Belanger has maintained a 'Buy' rating on Liquidia (NASDAQ:LQDA) and kept the price target at $18.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 6:17 pm

Liquidia and Pharmosa Biopharm have entered into an exclusive licensing agreement for the development and commercialization of L606 in North America. Liquidia will pay $10M upfront and $215M in milestone payments. L606 is an inhaled, sustained-release formulation of treprostinil, currently under clinical trial for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 9:52 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.